Immunotherapeutic method for increasing groundnut tolerance in a subject
View Patent ↗The present invention describes a new method for progressive desensitization of a subject to groundnut. More specifically, the invention relates to the immunotherapeutic method for increasing groundnut tolerance in an allergic subject using epicutaneous administration. The present invention is also relative to the use of a skin patch device for progressive desensitization of a subject to groundnut.
1. An immunotherapeutic method for increasing tolerance in a subject to groundnut, comprising:
repeatedly administering to the subject one or more proteins derived from groundnut via an epicutaneous route using a skin patch including a backing having a periphery adapted to create a hermetically closed chamber when applied to the subject's skin,
the backing carrying said one or more proteins in a dose sufficient to induce an immune reaction in the subject following application of the skin patch to the subject's skin,
said one or more proteins being removed from the backing following application of the patch device to the subject's skin and thereafter being delivered to the subject via the epicutaneous route,
said administration leading, on repetition, to a progressive increase in tolerance in the subject to groundnut,
said one or more proteins being formulated without any adjuvant.
2. A method according to claim 1 , wherein said one or more proteins are selected from ARAh1, ARAh2 and ARAh3 optionally in combination with other proteins derived from groundnut.
3. A method according to claim 1 , wherein said one or more proteins are administered in the form of an at least partially purified extract of groundnut.
4. A method according to claim 1 , wherein said one or more proteins are in dry form.
5. A method according to claim 4 , wherein said one or more proteins are in particulate form and attached to the backing without adhesive using electrostatic, Van der Waals forces, or both.
6. A method according to claim 4 , wherein said one or more proteins are in particulate form and attached to the backing using an adhesive coating on the backing.
7. A method according to claim 1 , further comprising loading said one or more proteins onto the backing by dissolving the proteins in a solvent, disposing the dissolved proteins on the backing, and evaporating the solvent to leave the proteins in particle form.
8. A method according to claim 1 , wherein said one or more proteins are dissolved or dispersed in a liquid.
9. A method according to claim 8 , wherein said one or more proteins in liquid form are held on the backing in a reservoir of adsorbent material.
10. A method of claim 1 , wherein condensation forms within the chamber following application of the patch device to the skin, which causes or enhances removal and epicutaneous delivery of the proteins.
11. The method of claim 10 , wherein condensation forms as a result of perspiration.
12. The method of claim 1 , wherein the device is applied without pre-treating the skin of the subject.
13. A method according to claim 1 , wherein the periphery of the backing has adhesive properties.
14. A method according to claim 1 , wherein the periphery of the backing has adhesive properties on moistured skin.
15. A method according to claim 1 , wherein said repeatedly administering comprises applying at least one patch, and then applying another at least one patch after a time period of at least 24 hours.
16. A method according to claim 1 , which method causes an increase in specific IgG levels.
17. A method according to claim 16 , which method causes an increase in specific IgG4 levels.
18. A method according to claim 1 , which method causes the raising of a Th1 response to the proteins administered.
19. A method according to claim 1 , which method causes an immune deviation from a dominant Th2 profile to a more balanced Th1/Th2 profile.
20. A skin patch comprising:
a backing having a periphery adapted to create a hermetically closed chamber when applied to skin,
the backing carrying one or more proteins derived from groundnut in a dose sufficient to induce an immune reaction in a subject following application of the skin patch to the subject's skin,
said one or more proteins derived from groundnut being removed from the backing following application of the skin patch to the subject's skin and thereafter being delivered to the subject via an epicutaneous route,
said one or more proteins being formulated without any adjuvant.
21. A kit comprising a plurality of skin patches according to claim 20 , each skin patch containing the same amount of groundnut allergen.